Get the Stockscreener App
235.17
1.70%
3.93
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $235.17, with a volume of 1.68M.
It is up +1.70% in the last 24 hours and up +2.20% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$231.24
Open:
$230.91
24h Volume:
1.68M
Relative Volume:
0.74
Market Cap:
$54.69B
Revenue:
$250.74B
Net Income/Loss:
$1.55B
P/E Ratio:
35.96
EPS:
6.5398
Net Cash Flow:
$4.39B
1W Performance:
-0.52%
1M Performance:
+2.20%
6M Performance:
+6.51%
1Y Performance:
+56.55%
1-Day Range:
$229.33
$235.27
1-Week Range:
$229.33
$258.30
52-Week Range:
$145.87
$258.30
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH vs MCK, COR, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
235.17 | 54.46B | 250.74B | 1.55B | 4.39B | 6.5398 |
MCK
Mckesson Corp
|
869.00 | 102.45B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
313.82 | 59.95B | 328.68B | 2.55B | 1.56B | 13.03 |
HSIC
Henry Schein Inc
|
89.77 | 10.11B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.27 | 1.26B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health CEO details M&A strategy and growth - Yahoo! Finance Canada
Reasons to Hold Hinge Health Stock in Your Portfolio for Now - TradingView
Monolithic Power Systems and Las Vegas Sands have been highlighted as Zacks Bull and Bear of the Day - TradingView
Cardinal Health Stock Hits a Record High After Earnings: Is CAH Still a Buy? - TradingView
Cardinal Health Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Wellington Group (CAH) discloses 6.34% beneficial stake in Cardinal Health - Stock Titan
Cardinal Health Stock Loses $912 Million as Recall Searches Test a $63.7 Billion Quarter - TechStock²
JPMorgan Chase & Co. Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price - MarketBeat
Cardinal Health: Q4 Presents Positive Signal For The Company's Long-Term Growth (NYSE:CAH) - Seeking Alpha
Can BWX Technologies' Nuclear Medicine Expansion Boost Growth? - TradingView
Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating - marketscreener.com
JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating - marketscreener.com
Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating - marketscreener.com
Citi Keeps Their Buy Rating on Cardinal Health (CAH) - theglobeandmail.com
Cardinal Health Is Maintained at Buy by Citigroup - Moomoo
Cardinal Health Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market - Sahm
Cardinal Health Analysts Increase Their Forecasts Following Q4 Results - webull.com
Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks - Yahoo Finance
Cardinal Health (NYSE:CAH) Given New $280.00 Price Target at Citigroup - MarketBeat
Cardinal Health Earnings: Can Perfection Get Priced In Twice? - MarketBeat
CAH Maintained by Evercore ISI Group -- Price Target Raised to $270 - GuruFocus
Cardinal Health Q4 Results: EPS beats by 20%, sales miss estimates - scanx.trade
Barclays Adjusts Cardinal Health Price Target to $275 From $258, Maintains Overweight Rating - marketscreener.com
Cardinal Health (NYSE:CAH) Cash Strength Faces A Valuation Test - Kalkine Media
Cardinal Health, Lumentum Holdings, Public Storage - TradingView
Evercore ISI Adjusts PT on Cardinal Health to $265 From $270, Maintains Outperform Rating - marketscreener.com
CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook - TradingView
UBS Adjusts Price Target on Cardinal Health to $280 From $274, Keeps Buy Rating - marketscreener.com
Keurig Dr Pepper Adds Cardinal Health CFO Aaron Alt to Board - citybiz
Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock - MarketBeat
Robert W. Baird Raises Cardinal Health (NYSE:CAH) Price Target to $274.00 - MarketBeat
Wells Fargo Adjusts Cardinal Health Price Target to $277 From $245, Maintains Overweight Rating - marketscreener.com
Mizuho Securities Adjusts Cardinal Health PT to $250 From $240, Maintains Outperform Rating - marketscreener.com
Baird Adjusts Cardinal Health Price Target to $274 From $251, Maintains Outperform Rating - marketscreener.com
Mizuho raises Cardinal Health stock price target to $250 on earnings - Investing.com Canada
Cardinal Health stock (CAH) climbs after 14% EPS growth forecast offset by 25% decline in cash flow - TechStock²
Cardinal Health’s Q4 Earnings Explained: A Revenue Miss, a Profit Beat - TIKR.com
Handelsbanken Fonder AB Acquires 14,919 Shares of Cardinal Health, Inc. $CAH - MarketBeat
Morgan Stanley Adjusts PT on Cardinal Health to $265 From $255, Keeps Overweight Rating - marketscreener.com
Cardinal Health (CAH) Stock Richly Valued Despite $5b Cash Flow Strength - Sahm
Cardinal Health (NYSE:CAH) Sets New 52-Week High After Earnings Beat - MarketBeat
Cardinal Health, Inc. Stock 12‑Month Price Target Raised to $258.77, Implies 9% Upside - TradingView
Cardinal Health, Inc. (CAH) Stock Forecasts - Yahoo Finance
Cardinal Health Inc (CAH) (Q4 2026) Earnings Call Highlights: Record EPS Growth and Robust ... - Yahoo Finance
Cardinal Health, Inc. Announces Quarterly Dividend of $0.52 (NYSE:CAH) - MarketBeat
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Cardinal Health Inc (CAH) (Q4 2026) Earnings Call Highlights: Re - GuruFocus
Earnings To Watch: Cardinal Health (CAH) Reports Q2 Results Tomorrow - Yahoo Finance
Cardinal Health Earnings: Revenue Slowdown on Highlight but Earnings Power Still Exceptional - Morningstar
Cardinal Wraps Up Fiscal 2026 With Revenue Softness but Margin Expansion and Earnings Growth Impress - Morningstar
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):